We believe great partnerships create great possibilities and are inspired by our partners
As a global biopharmaceutical company, we leverage our agility, R&D capabilities and global footprint to develop valuable business partnerships that fuel tomorrow’s breakthrough discoveries across our three therapeutic areas: Oncology, Rare Disease and Neuroscience. External innovation is at the heart of our strategy. We believe in the expertise of our partners and value the opportunity to collaborate, bringing our skills, experience and global reach to accelerate innovation to bring new medicines to patients.
Exclusively sourcing our pipeline through external innovation, we have no internal competing pipeline as we recognize the best science is delivered in biotech and academic institutions. We are proud our team comprises talents attracted from Pharma, biotech and academia, to drive shared success through creative collaborations.
Partnering with Ipsen
As a mid-size pharma, we leverage our agility, R&D capabilities and global footprint to develop valuable business partnerships that fuel tomorrow’s breakthrough discoveries across our three therapeutic areas: Oncology, Rare Disease and Neuroscience. External innovation is at the heart of our strategy. We believe in the expertise of our partners and value the opportunity to collaborate, bringing our skills, experience and global reach to accelerate innovation to bring new medicines to patients.
Great partnerships create great possibilities — hear from the people driving collaboration and innovation at Ipsen.
Strong and solid mid-size pharmaceutical company delivering > €3.4bn sales in 2024 with growth across all regions and therapeutic areas.
We have now added >20 programs across every stage of development to Ipsen’s pipeline since 2021.
We now have 7 assets projected to deliver >500m sales by 2027, this was achieved together with our partners through accelerating, de-risking & maximizing these programs.
We intend to continue building this strong future for Ipsen through collaborations & acquisitions.
Our Partnering Impact
Explore our key milestones and partnering successes.
Impact across the globe
Represented in 88 countries, our commercial sales have strong coverage across Europe (39%), Europe (39%) the rest of the world (26%) with our medicines showing best-in-class commercial performance.
Strength in numbers: a strong pipeline
Since 2020, Ipsen has brought in more than 30 best- or first-in-class programs across at our pipeline at every stage of development and plans are in place to acquire more.
Connecting patients to our therapies
Our 5,000 colleagues in more than 40 countries, and our partnerships around the world, enable us to bring medicine to patients in >100 countries.
Solidifying oncology partnerships
Ipsen has finalized several licensing agreements, adding innovative modalities – such as antibody-drug conjugates and T cell engagers – to our early development pipeline. We also secured a licensing agreement with Day One Pharmaceuticals for a first-in-class treatment for pediatric low-grade glioma, expanding new possibilities for this patient group.
New modalities in neuroscience
In 2024, we entered an exclusive global collaboration with Skyhawk Therapeutics to discover and develop novel small molecules that modulate RNA for rare neurological diseases.
Image not fully aligned with the guidelines
Marengo Case Study
Find out more about how we approach partnerships at Ipsen, where every program is a priority within our pipeline. We sat down with Zhen Su, CEO Marengo, to discuss our partnership and how we undertake a one team approach to accelerate innovation for the patients who are waiting.
Contact the partnering team
At Ipsen, partnering is personal and purpose-led. Our team is committedto success and has the expertise to deliver it. Contact us to see howtogether, we can accelerate innovation for patients.
Investors
At Ipsen, we see investors as vital partners in advancing our mission.Ipsen provides comprehensive investor information, including ourfinancial updates, reports and events calendar, plus shareholder newsand regulated information in our dedicated investor pages.
Learn more
